Salivary duct carcinoma in the mandible.
We reported 1 case of salivary duct carcinoma (SDC) in the mandible. The patient complained of pain and a growing mass in the right submandibular area for approximately 2 months. On clinical examination, there was a mass under the right angle of the mandible with a size of approximately 3 × 3 cm, a smooth surface, a poor activity, and a hard texture. Panoramic radiograph revealed poorly circumscribed area. Computed tomography presented mandible central destruction. Biopsy examination showed a malignant tumor that originated in the central epithelium of the mandible. An operation of unilateral selective neck dissection and mandible subtotal ectomy was performed. Postoperative pathology reported SDC. The patient received postoperative radiation and stayed alive at last follow-up without disease recurrence. Ablative resection and postoperative radiotherapy were the standard treatment stratagem for SDC, but trastuzumab therapy might play a key role in treating the disease in future.
From the *Department of Pediatric Dentistry, and †Department of Oromaxillofacial-Head and Neck Surgery and Department of Oral and Maxillofacial Surgery, School of Stomatology, China Medical University, Shenyang, Liaoning, PR China.
Shuang
S
Shi
Qi-Gen
QG
Fang
Changfu
C
Sun
D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D044584:Carcinoma, Ductal / Q000175:diagnosis* / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008334:Mandible / Q000000981:diagnostic imaging / Q000601:surgery; D008875:Middle Aged; D037981:Neck Dissection; D010027:Osteotomy / Q000379:methods; D011862:Radiography, Panoramic / Q000379:methods; D018714:Radiotherapy, Adjuvant; D018987:Salivary Ducts / Q000473:pathology* / Q000601:surgery; D012468:Salivary Gland Neoplasms / Q000175:diagnosis* / Q000601:surgery; D014057:Tomography, X-Ray Computed / Q000379:methods; D000068878:Trastuzumab
D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068878:Trastuzumab